Endometriosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Endometriosis Emerging Therapy and TPP Insights

Thelansis’s “Endometriosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Endometriosis Overview

Endometriosis is a chronic, estrogen-dependent, and highly debilitating systemic inflammatory disease defined by the ectopic proliferation of endometrial-like tissue (glands and stroma) outside the uterine cavity. Most frequently localizing to the pelvic peritoneum, ovaries, and uterosacral ligaments, the disease is clinically classified into three distinct anatomic phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can aggressively invade the bowel and bladder. Far from a benign condition, these ectopic lesions undergo cyclic, estrogen-driven bleeding that triggers intense localized inflammation, fibrosis, and adhesion formation, manifesting clinically as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and profound infertility. While historically categorized by the surgically evaluated ASRM staging system (ranging from Stage I/Minimal to Stage IV/Severe)—which notoriously correlates poorly with actual pain severity—the modern clinical paradigm increasingly relies on advanced imaging and symptom-driven management. Because there is currently no definitive cure, the standard of care centers on multimodal symptom control; this includes conservative surgical excision combined with aggressive medical suppression of the estrogenic environment, utilizing continuous hormonal contraceptives, progestins, and most recently, targeted oral gonadotropin-releasing hormone (GnRH) antagonists (such as elagolix or relugolix) to achieve durable pain relief and improve patient quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Endometriosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026